Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

By pinki shah / May 14, 2022

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 1,626 - 1,650 of 2,573

«
1
…
64
65
66
67
68
…
103
»

Locally Advanced NSCLC- Radiation Therapy

Locally Advanced NSCLC- Radiation Therapy

By: Lucas K. Vitzthum, MD, MAS

Locally Advanced NSCLC- Radiation Therapy

Locally Advanced NSCLC- Radiation Therapy

By: Lucas Vitzthum, MD

Locally Advanced NSCLC- Radiation Therapy

Locally Advanced NSCLC- Radiation Therapy

By: Lucas Vitzthum, MD

Surgery for Early-Stage NSCLC

Surgery for Early-Stage NSCLC

By: Luis A. Godoy, MD, MAS, FACS

Surgery for Early-Stage NSCLC

Surgery for Early-Stage NSCLC

By: Luis A. Godoy, MD, MAS, FACS

Squamous Cell Carcinoma: What are the Standards and Potential Pathways in Development

Squamous Cell Carcinoma: What are the Standards and Potential Pathways in Development

By: Luis Corrales-Rodriguez, MD

Challenges in Immunotherapy in NSCLC

Challenges in Immunotherapy in NSCLC

By: Luis E Raez - MD - FACP - FCCP

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

By: Luis E Raez, MD, FACP, FCCP

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

By: Luis E Raez, MD, FACP, FCCP

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

Lung Cancer Neoadjuvant and Adjuvant Immunotherapy

By: Luis E Raez, MD, FACP, FCCP

Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1

Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1

By: Luis E. Raez MD

Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1

Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1

By: Luis E. Raez MD

NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer

NTRK, Exon 20 insertions, and Potential Novel Pathways in Lung Cancer

By: Luis E. Raez, MD

By: Luis E. Raez, MD

Immunotherapy in Lung Cancer

Immunotherapy in Lung Cancer

By: Luis E. Raez, MD

Agnostic Tumor Drug Development

Agnostic Tumor Drug Development

By: Luis E. Raez, MD

Immunotherapy in Lung Cancer

Immunotherapy in Lung Cancer

By: Luis E. Raez, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

By: Luis E. Raez, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

By: Luis E. Raez, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

By: Luis E. Raez, MD

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures?

By: Luis E. Raez, MD

Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease

Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease

By: Luis E. Raez, MD, FACP

Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease

Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease

By: Luis E. Raez, MD, FACP

Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

By: Luis E. Raez, MD, FACP

Controversies in Lung Cancer:
Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC

By: Luis E. Raez, MD, FACP

«
1
…
64
65
66
67
68
…
103
»

Post navigation

← Previous View

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok